Jiangsu Jibeier Pharmaceutical Co Ltd Working Capital to Net Assets Ratio
Jiangsu Jibeier Pharmaceutical Co Ltd working capital to net assets ratio. Jiangsu Jibeier Pharmaceutical Co Ltd (688566) has a Working Capital to Net Assets ratio of 44.9% as of March 2026. Working capital of CN¥1.12 Billion (current assets of CN¥1.26 Billion minus current liabilities of CN¥134.31 Million) is measured against net assets of CN¥2.50 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of Jiangsu Jibeier Pharmaceutical Co Ltd (2016–2025)
Working capital to net assets ratio of Jiangsu Jibeier Pharmaceutical Co Ltd from 2016 to 2025. This chart shows how Jiangsu Jibeier Pharmaceutical Co Ltd's Working Capital to Net Assets ratio has evolved across 10 annual periods from 2016 to 2025. As of March 2026, the ratio stands at 44.9%, reflecting working capital of CN¥1.12 Billion against net assets of CN¥2.50 Billion CNY. See Jiangsu Jibeier Pharmaceutical Co Ltd liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Jiangsu Jibeier Pharmaceutical Co Ltd Working Capital to Net Assets Ratio by Year (2016–2025)
Jiangsu Jibeier Pharmaceutical Co Ltd working capital to net assets ratio by year from 2016 to 2025. The table below presents the year-by-year Working Capital to Net Assets ratio for Jiangsu Jibeier Pharmaceutical Co Ltd from 2016 to 2025, covering 10 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see Jiangsu Jibeier Pharmaceutical Co Ltd (688566) total assets.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 44.0% | CN¥1.08 Billion | CN¥2.45 Billion | CN¥1.25 Billion | CN¥177.01 Million | ▼ -5.7 pp |
| 2024 | 49.7% | CN¥1.12 Billion | CN¥2.25 Billion | CN¥1.30 Billion | CN¥185.19 Million | ▲ +1.5 pp |
| 2023 | 48.2% | CN¥920.84 Million | CN¥1.91 Billion | CN¥1.13 Billion | CN¥210.31 Million | ▼ -15.3 pp |
| 2022 | 63.5% | CN¥1.08 Billion | CN¥1.69 Billion | CN¥1.26 Billion | CN¥181.36 Million | ▼ -16.2 pp |
| 2021 | 79.7% | CN¥1.28 Billion | CN¥1.61 Billion | CN¥1.41 Billion | CN¥124.06 Million | ▼ -10.7 pp |
| 2020 | 90.5% | CN¥1.43 Billion | CN¥1.58 Billion | CN¥1.51 Billion | CN¥84.01 Million | ▲ +26.6 pp |
| 2019 | 63.8% | CN¥300.36 Million | CN¥470.46 Million | CN¥365.44 Million | CN¥65.09 Million | ▲ +4.7 pp |
| 2018 | 59.2% | CN¥211.63 Million | CN¥357.68 Million | CN¥272.89 Million | CN¥61.26 Million | ▼ -3.7 pp |
| 2017 | 62.9% | CN¥277.24 Million | CN¥440.76 Million | CN¥329.36 Million | CN¥52.12 Million | ▲ +8.0 pp |
| 2016 | 54.9% | CN¥199.42 Million | CN¥363.15 Million | CN¥281.99 Million | CN¥82.57 Million | — |